SLC22A4 and chronic myelogenous leukemia, BCR-ABL1 positive: A well-known OCTN1 polymorphism, rs1050152-CT, clearly associated with inflammatory bowel diseases [29], has been associated with a major molecular response (MMR) to imatinib, which is the first-line drug used for the treatment of patients affected by chronic myeloid leukemia (CML) [39].